Literature DB >> 35065233

Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site.

Nicholas L Yan1, Reji Nair1, Alan Chu2, Ian A Wilson3, Kristen A Johnson2, Gareth J Morgan4, Jeffery W Kelly5.   

Abstract

In immunoglobulin light chain (LC) amyloidosis, the misfolding, or misfolding and misassembly of LC a protein or fragments thereof resulting from aberrant endoproteolysis, causes organ damage to patients. A small molecule "kinetic stabilizer" drug could slow or stop these processes and improve prognosis. We previously identified coumarin-based kinetic stabilizers of LCs that can be divided into four components, including a "linker module" and "distal substructure". Our prior studies focused on characterizing carbamate, hydantoin, and spirocyclic urea linker modules, which bind in a solvent-exposed site at the VL-VL domain interface of the LC dimer. Here, we report structure-activity relationship data on 7-diethylamino coumarin-based kinetic stabilizers. This substructure occupies the previously characterized "anchor cavity" and the "aromatic slit". The potencies of amide and urea linker modules terminating in a variety of distal substructures attached at the 3-position of this coumarin ring were assessed. Surprisingly, crystallographic data on a 7-diethylamino coumarin-based kinetic stabilizer reveals that the urea linker module and distal substructure attached at the 3-position bind a solvent-exposed region of the full-length LC dimer distinct from previously characterized sites. Our results further elaborate the small-molecule binding surface of LCs that could be occupied by potent and selective LC kinetic stabilizers.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amyloidosis; Crystal structure; Immunoglobulin; Kinetic stabilizer; Light chain; Proteolysis

Mesh:

Substances:

Year:  2022        PMID: 35065233      PMCID: PMC8857066          DOI: 10.1016/j.bmcl.2022.128571

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  34 in total

Review 1.  Immunoglobulin light chain amyloidosis.

Authors:  Giampaolo Merlini; Raymond L Comenzo; David C Seldin; Ashutosh Wechalekar; Morie A Gertz
Journal:  Expert Rev Hematol       Date:  2013-12-18       Impact factor: 2.929

Review 2.  Systemic immunoglobulin light chain amyloidosis.

Authors:  Giampaolo Merlini; Angela Dispenzieri; Vaishali Sanchorawala; Stefan O Schönland; Giovanni Palladini; Philip N Hawkins; Morie A Gertz
Journal:  Nat Rev Dis Primers       Date:  2018-10-25       Impact factor: 52.329

3.  Identification of Chemical and Pharmacological Chaperones for Correction of Trafficking-Deficient Mutant Cyclic Nucleotide-Gated A3 Channels.

Authors:  Joachim Täger; Bernd Wissinger; Susanne Kohl; Peggy Reuter
Journal:  Mol Pharmacol       Date:  2021-04-07       Impact factor: 4.436

4.  AL-Base: a visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences.

Authors:  Kip Bodi; Tatiana Prokaeva; Brian Spencer; Maurya Eberhard; Lawreen H Connors; David C Seldin
Journal:  Amyloid       Date:  2009-03       Impact factor: 7.141

5.  Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease.

Authors:  T Okumiya; S Ishii; T Takenaka; R Kase; S Kamei; H Sakuraba; Y Suzuki
Journal:  Biochem Biophys Res Commun       Date:  1995-09-25       Impact factor: 3.575

6.  Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).

Authors:  Roshini S Abraham; Susan M Geyer; Tammy L Price-Troska; Cristine Allmer; Robert A Kyle; Morie A Gertz; Rafael Fonseca
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

Review 7.  Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease.

Authors:  Tae-Un Han; Richard Sam; Ellen Sidransky
Journal:  Front Cell Dev Biol       Date:  2020-05-19

8.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

Authors:  Mathew S Maurer; Jeffrey H Schwartz; Balarama Gundapaneni; Perry M Elliott; Giampaolo Merlini; Marcia Waddington-Cruz; Arnt V Kristen; Martha Grogan; Ronald Witteles; Thibaud Damy; Brian M Drachman; Sanjiv J Shah; Mazen Hanna; Daniel P Judge; Alexandra I Barsdorf; Peter Huber; Terrell A Patterson; Steven Riley; Jennifer Schumacher; Michelle Stewart; Marla B Sultan; Claudio Rapezzi
Journal:  N Engl J Med       Date:  2018-08-27       Impact factor: 91.245

9.  Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.

Authors:  Luca Oberti; Paola Rognoni; Alberto Barbiroli; Francesca Lavatelli; Rosaria Russo; Martina Maritan; Giovanni Palladini; Martino Bolognesi; Giampaolo Merlini; Stefano Ricagno
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

10.  Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis.

Authors:  Gareth J Morgan
Journal:  Molecules       Date:  2021-06-11       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.